IP Library › Granted Patent US 12,404,242
Granted Patent B2
US 12,404,242 · App. 18/718,991 · Granted Sep 2, 2025

Compositions and methods for making and using small molecules in the treatment of cancer

Inventors: Vijay Gokhale (Houston, TX); Teri C. Suzuki (Houston, TX)
Assignee: Reglagene, Inc.
C07D213/643A61K31/426A61K31/44A61K31/505C07D239/34C07D277/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,242
App. No.
18/718,991
Granted
Sep 2, 2025
Kind
B2
Abstract

Embodiments of the instant disclosure relate to novel compounds, compositions, and methods for treating health conditions. In certain embodiments, methods of treating cancers can include administering an effective amount of at least one novel compound disclosed herein to a subject having cancer. In some embodiments, methods of treating cancers can include administering a pharmaceutical composition disclosed herein to a subject, the composition including at least one of the novel compounds disclosed herein, and optionally, one additional agent.

Claims (10)

1. A compound according to formula (I),

or formula (II),

wherein:

R 1 and R 6 are each independently selected from the group consisting of:

R 2 is selected from the group consisting of CH 3 or F;

wherein R 3 and R 7 are each a 5- or 6-membered heteroaryl unsubstituted or optionally substituted with one or more groups independently selected from the group consisting of alkyl, alkylamino, halogen, alkylhalide, cyano, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxyl, heterocyclic alkoxyl, cycloalkylthio, and heterocyclic alkylthio,

R 4 and R 5 are each independently selected from the group consisting of H and F; and

R 8 is selected from the group consisting of CH 3 and H.

2. The compound according to claim 1 , wherein R 3 and R 7 are each independently selected from the group consisting of:

3. A compound selected from the group consisting of:

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2024
From: GOKHALE, VIJAY; SUZUKI, TERI C.
To: REGLAGENE HOLDING, INC.
Reel/Frame 067845/0787 →
CHANGE OF NAME Recorded Jun 26, 2024
From: REGLAGENE HOLDING, INC.
To: REGLAGENE, INC.
Reel/Frame 067855/0698 →
Continuity (2)
Provisional Application 63291144 · Dec 17, 2021
Related Publication 20250109105A1 · Apr 3, 2025
References Cited (76)
US 7144911B2 · Flynn et al. · 2006 [cited by applicant]
US 7342037B2 · Flynn et al. · 2008 [cited by applicant]
US 7968536B2 · Cossrow et al. · 2011 [cited by applicant]
US 8017629B2 · Cheng et al. · 2011 [cited by applicant]
US 8034954B2 · Pacofsky et al. · 2011 [cited by applicant]
US 8080567B2 · Oxford et al. · 2011 [cited by applicant]
US 8124632B2 · Rossignol et al. · 2012 [cited by applicant]
US 8158636B2 · Ibrahim et al. · 2012 [cited by applicant]
US 8431605B2 · Hadida Ruah et al. · 2013 [cited by applicant]
US 8703761B2 · Forster et al. · 2014 [cited by applicant]
US 8722702B2 · Zhang et al. · 2014 [cited by applicant]
US 8802657B2 · Cossrow et al. · 2014 [cited by applicant]
US 8822513B2 · Lu et al. · 2014 [cited by applicant]
US 8921576B2 · Ogamino et al. · 2014 [cited by applicant]
US 9115120B2 · Jones et al. · 2015 [cited by applicant]
US 9334242B2 · Lu et al. · 2016 [cited by applicant]
US 9447049B2 · Li et al. · 2016 [cited by applicant]
US 9550768B2 · Zhang et al. · 2017 [cited by applicant]
US 11028061B2 · Kelly et al. · 2021 [cited by applicant]
US 11078171B2 · Shapiro et al. · 2021 [cited by applicant]
US 11084811B2 · Li et al. · 2021 [cited by applicant]
US 11149033B2 · Min et al. · 2021 [cited by applicant]
US 20090036467A1 · Rossignol et al. · 2009 [cited by applicant]
US 20090069310A1 · Flynn et al. · 2009 [cited by applicant]
US 20090136472A1 · Westman et al. · 2009 [cited by applicant]
US 20100076029A1 · Bartolozzi et al. · 2010 [cited by applicant]
US 20100081644A1 · Bartolozzi et al. · 2010 [cited by applicant]
US 20100152162A1 · Uesaka et al. · 2010 [cited by applicant]
US 20100331338A1 · Burgdorf et al. · 2010 [cited by applicant]
US 20110312932A1 · Bartolozzi et al. · 2011 [cited by applicant]
US 20120010184A1 · Bartolozzi et al. · 2012 [cited by applicant]
US 20120071524A1 · Lu et al. · 2012 [cited by applicant]
US 20120108576A1 · Zhang et al. · 2012 [cited by applicant]
US 20200024270A1 · Li et al. · 2020 [cited by applicant]
US 20210186022A1 · Pouliot et al. · 2021 [cited by applicant]
US 20220024912A1 · Li et al. · 2022 [cited by applicant]
US 20220089532A1 · Nojima et al. · 2022 [cited by applicant]
US 20220298168A1 · Le Bourdonnec et al. · 2022 [cited by applicant]
US 20230029266A1 · Cevikbas et al. · 2023 [cited by applicant]
EP 2055697A1 · 2009 [cited by applicant]
WO 2005075435A1 · 2005 [cited by applicant]
WO 2006004636A2 · 2006 [cited by applicant]
WO 2007010273A2 · 2007 [cited by applicant]
WO 2006122011A2 · 2007 [cited by applicant]
WO 2008065409A2 · 2008 [cited by applicant]
WO 2008090327A1 · 2008 [cited by applicant]
WO 2009085256A1 · 2009 [cited by applicant]
WO 2009106203A1 · 2009 [cited by applicant]
WO 2010036630A1 · 2010 [cited by applicant]
WO 2010133312A1 · 2010 [cited by applicant]
WO 2012103583A1 · 2012 [cited by applicant]
WO 2013131018A1 · 2013 [cited by applicant]
WO 2016160938A1 · 2016 [cited by applicant]
WO 2017006282A1 · 2017 [cited by applicant]
WO 2018069863A1 · 2018 [cited by applicant]
WO 2018087160A1 · 2018 [cited by applicant]
WO 2019183587A1 · 2019 [cited by applicant]
WO 2020198026A1 · 2020 [cited by applicant]
WO 2021092240A1 · 2021 [cited by applicant]
WO 2021115375A1 · 2021 [cited by applicant]
WO 2021163192A1 · 2021 [cited by applicant]
WO 2021216656A1 · 2021 [cited by applicant]
WO 2021216660A1 · 2021 [cited by applicant]
WO 2021248231A1 · 2021 [cited by applicant]
WO 2021252555A1 · 2021 [cited by applicant]
WO 2022063152A1 · 2022 [cited by applicant]
WO 2022174031A1 · 2022 [cited by applicant]
WO 2023274251A1 · 2023 [cited by applicant]
WO 2023028238A1 · 2023 [cited by applicant]
Registry No. 1972-67-4, File REGISTRY on STN, entered STN Nov. 16, 1984. [cited by examiner]
Patron et al. “Abstract A023: Brain penetrant small molecule for the treatment of glioblastoma.” Cancer Research 84.5_Supplement_1 (2024): A023-A023. [cited by applicant]
Wager et al. “Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties.” ACS chemical neuroscience 1.6 (2010): 435-449. [cited by applicant]
Alavijeh et al. “Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.” NeuroRx 2 (2005): 554-571. [cited by applicant]
Sun et al. “Why 90% of clinical drug development fails and how to improve it ?. ” Acta Pharmaceutica Sinica B 12.7 (2022): 3049-3062. [cited by applicant]
Van de Waterbeemd et al. “Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors.” Journal of drug targeting 6.2 (1998): 151-165. [cited by applicant]
Office Action for U.S. Appl. No. 18/590,806, dated Aug. 12, 2024. [cited by applicant]